Breaking News Instant updates and real-time market news.

AMGN

Amgen

$185.60

-0.69 (-0.37%)

, SCR

Simcere

16:03
09/26/17
09/26
16:03
09/26/17
16:03

Amgen and Simcere execute agreement to co-develop four biosimilars in China

Amgen (AMGN) and Simcere Pharmaceutical Group (SCR) announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology. Under the terms of the agreement, Amgen will remain responsible for the co-development, marketing approval applications and manufacturing of the biosimilars. Simcere will be responsible for distribution and commercialization in China, while Amgen will have a limited right to co-promote the products. The biosimilars included in the agreement are a part of Amgen's existing biosimilars portfolio. Specific financial terms of the agreement were not disclosed.

AMGN

Amgen

$185.60

-0.69 (-0.37%)

SCR

Simcere

  • 08

    Nov

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

AMGN Amgen
$185.60

-0.69 (-0.37%)

09/07/17
PIPR
09/07/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron selloff today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes shares of Regeneron Pharmaceuticals (REGN) are trading lower after Phase IIb readouts from competitors Amgen (AMGN) and AstraZeneca (AZN) in asthma and AbbVie (ABBV) in atopic dermatitis met their primary endpoints. The analyst does not see an "immediate competitive threat" to Regeneron's Dupixent, which he says has successfully launched in atopic dermatitis following FDA approval in March. He recommends buying the shares on today's selloff ahead of expected "positive" Phase III Dupixent asthma data. Dupixent maintains at least a two-year lead ahead of these competitive agents, Tenthoff tells investors in an intraday research note. The analyst reiterates an Overweight rating on Regeneron with a $557 price target.
09/14/17
RBCM
09/14/17
INITIATION
Target $192
RBCM
Sector Perform
Amgen initiated with a Sector Perform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Amgen with a Sector Perform and an $192 price target.
09/21/17
UBSW
09/21/17
NO CHANGE
Target $500
UBSW
Buy
Regeneron price target lowered to $500 from $535 at UBS
UBS analyst Carter Gould lowered his price target on Regeneron (REGN) to $500 from $535 citing increased Dupixent competition after Amgen (AMGN) and AstraZeneca (AZN) reported data on their own asthma drug earlier this month and AbbVie (ABBV) reported results in an atopic dermatitis study. While he noted that definitive 12-month phase 3 data from these competitors is likely more than 20 months away, he also lowered his Dupixent peak sales estimate to $4.8B from $6.5B. He keeps a Buy rating on Regeneron shares, as he believes pipeline products including nesvacumab and REGN2810 offer a path to longer-term upside.
09/25/17
JEFF
09/25/17
NO CHANGE
Target $200
JEFF
Buy
Jefferies explains how Amgen can re-rate higher like AbbVie
Jefferies analyst Michael Yee believes the 2018-2020 consensus estimates for Amgen (AMGN) may be too low if Mylan's (MYL) biosimilar of Neulasta doesn't get approved next month. The Biosimilar User Fee Act date is October 9. Investors may become more confident in the durability of Amgen's franchise given that AbbVie (ABBV) defended Humira and re-rated to a higher valuation, Yee tells investors in a research note. The key issue keeping Amgen's price-to-earnings multiple below peers at 12 to 13 times over the past couple of years is investor fear of biosimilars primarily against Neulasta and Enbrel, Yee argues. He sees a failed approval for Mylan as setting the tone for a higher multiple like AbbVie. The analyst has a Buy rating on Amgen shares with a $200 price target.
SCR Simcere

TODAY'S FREE FLY STORIES

NFLX

Netflix

09:00
10/17/17
10/17
09:00
10/17/17
09:00
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Fed funds futures are modestly lower, having unwound early gains »

Fed funds futures are…

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Industrial Production to be reported at 09:15 »

September Industrial…

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Industrial Production Capacity Utilization Rate to be reported at 09:15 »

September Industrial…

ACN

Accenture

$139.09

-0.11 (-0.08%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Hot Stocks
Accenture enters into exclusive negotiations to acquire Altima »

Accenture has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Earnings
Johnson & Johnson backs FY17 revenue view $75.9B-$76.2B, consensus $75.83 »

Guidance in constant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

LRCX

Lam Research

$192.36

2.46 (1.30%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Recommendations
Lam Research analyst commentary  »

Lam Research added to US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:57
10/17/17
10/17
08:57
10/17/17
08:57
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

08:56
10/17/17
10/17
08:56
10/17/17
08:56
General news
Redbook Store Sales data reported »

Week of 10/14 Redbook…

SRPT

Sarepta

$50.73

0.16 (0.32%)

08:56
10/17/17
10/17
08:56
10/17/17
08:56
Recommendations
Sarepta analyst commentary  »

Sarepta approaching…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

NFLX

Netflix

$202.68

3.19 (1.60%)

, GE

General Electric

$23.36

0.38 (1.65%)

08:55
10/17/17
10/17
08:55
10/17/17
08:55
Options
Notable open interest changes for October 17th »

Monday's total…

NFLX

Netflix

$202.68

3.19 (1.60%)

GE

General Electric

$23.36

0.38 (1.65%)

CMCSA

Comcast

$36.61

0.6 (1.67%)

BAC

Bank of America

$26.24

0.41 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

08:55
10/17/17
10/17
08:55
10/17/17
08:55
General news
The U.S. trade price report beat estimates »

The U.S. trade price…

NOW

ServiceNow

$121.40

-0.89 (-0.73%)

08:55
10/17/17
10/17
08:55
10/17/17
08:55
Conference/Events
ServiceNow to hold a forum »

NowForum 2017 is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

  • 26

    Oct

  • 11

    Dec

GSM

Ferroglobe

$14.56

0.39 (2.75%)

08:55
10/17/17
10/17
08:55
10/17/17
08:55
Conference/Events
Ferroglobe to hold investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 14

    Nov

  • 15

    Nov

MSBI

Midland States

$33.03

-0.07 (-0.21%)

08:55
10/17/17
10/17
08:55
10/17/17
08:55
Conference/Events
Midland States to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 27

    Oct

  • 15

    Nov

HPE

HP Enterprise

$14.86

-0.03 (-0.20%)

08:53
10/17/17
10/17
08:53
10/17/17
08:53
Initiation
HP Enterprise initiated  »

HP Enterprise initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:51
10/17/17
10/17
08:51
10/17/17
08:51
Hot Stocks
Johnson & Johnson says Puerto Rico hurricane had limited impact on company »

Says impact was limited…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

PX

Praxair

$141.29

-0.92 (-0.65%)

08:51
10/17/17
10/17
08:51
10/17/17
08:51
Hot Stocks
Praxair signs long-term agreement to supply nitrogen to GLOBALFOUNDRIES »

Praxair has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ERII

Energy Recovery

$8.21

0.02 (0.24%)

08:49
10/17/17
10/17
08:49
10/17/17
08:49
Initiation
Energy Recovery initiated  »

Energy Recovery initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 16

    May

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:49
10/17/17
10/17
08:49
10/17/17
08:49
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

CSX

CSX

$52.84

0.01 (0.02%)

08:49
10/17/17
10/17
08:49
10/17/17
08:49
Hot Stocks
CSX expects Q4 volume to be neutral »

CSX has a favorable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 29

    Oct

  • 30

    Oct

BOLD

Audentes Therapeutics

$25.00

-3.075 (-10.95%)

08:47
10/17/17
10/17
08:47
10/17/17
08:47
Initiation
Audentes Therapeutics initiated  »

Audentes Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

MS

Morgan Stanley

$48.94

0.64 (1.33%)

08:46
10/17/17
10/17
08:46
10/17/17
08:46
Hot Stocks
Morgan Stanley: MiFID to be 'a little bumpy,' not everyone ready for switchover »

Says believes MiFID will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:46
10/17/17
10/17
08:46
10/17/17
08:46
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

DNKN

Dunkin' Brands

$55.34

-0.13 (-0.23%)

08:46
10/17/17
10/17
08:46
10/17/17
08:46
Recommendations
Dunkin' Brands analyst commentary  »

Dunkin' Brands may…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 01

    Nov

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.